Phaseline

Companies › ReCode Therapeutics

ReCode Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RCT2100
CFTR mRNA therapeutic
CFTRPhase 2Cystic FibrosisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06237335RCT2100Phase 2Cystic FibrosisRespiratoryNov 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CFTR (1)

Companies with the same targets

Vertex Pharmaceuticals Napo Pharmaceuticals 4D Molecular Therapeutics Napo Therapeutics Qanatpharma Krystal Biotech Boehringer Ingelheim Arcturus Therapeutics

Companies built like this

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense Anagram Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.